Assessment of Canadian provincial expenditures in depressed patients treated with venlafaxine XR versus SSRIs: The APEX Study

Current Medical Research and Opinion

Volumn 22, Issue 1, 2006, Pages 83-94

  Monfared, A A Tahami ^a,b   Han, D ^c   Sheeny, O ^a   Bexton, B ^d   LeLorier, J ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

^c Wyeth Pharmaceuticals   (Canada)

^d HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

Antidepressants; Depression; Direct medical cost; Drug utilization; Persistence; Selective serotonin reuptake inhibitors (SSRIs); Venlafaxine

Indexed keywords

AMFEBUTAMONE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CENTRAL NERVOUS SYSTEM AGENTS; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PAROXETINE; REVERSIBLE INHIBITOR OF MONOAMINE OXIDASE TYPE A; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE; VENLAFAXINE XR;

ADULT; AGED; ARTICLE; CANADA; CLINICAL FEATURE; COMORBIDITY; CONFIDENCE INTERVAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEPRESSION; DRUG CHOICE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONEY; MULTIVARIATE ANALYSIS; UNIVARIATE ANALYSIS; BLOOD SAMPLING; CHROMOSOME ABERRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN CELL; IRAN; LYMPHOCYTE; OCCUPATIONAL EXPOSURE; RADIATION DOSE; RADIATION EXPOSURE; RADIATION RESPONSE; RADIOLOGY DEPARTMENT; REVIEW; WORKER;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CANADA; CYCLOHEXANOLS; DEPRESSION; DIRECT SERVICE COSTS; FEMALE; HEALTH EXPENDITURES; HUMANS; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS;

EID: 33746781340     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X80314     Document Type: Article

References (60)

1. Andrade L, Caraveo-Anduaga JJ, Berglund P, Bijl RV, De Graaf R, Vollebergh W et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res 2003;12:3-21
2. Health Canada. A report on mental illnesses in Canada; Chapter 1: Mental illnesses in Canada: an overview. 2002. Ottawa (ON), Health Canada. Available from: www.phac-aspc.gc.ca/publicat/ miic-mmac/. [Last accessed 11 October 2005]
3. Hirschfeld RM, Keller MB, Panico S, Arons BS, Barlow D, Davidoff F et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997;277:333-40
4. Nutting PA, Rost K, Dickinson M, Werner JJ, Dickinson P, Smith JL et al. Barriers to initiating depression treatment in primary care practice. J Gen Intern Med 2002;17:103-11
5. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-1504
6. Parikh SV, Lam RW. Clinical guidelines for the treatment of depressive disorders, I. Definitions, prevalence, and health burden. Can J Psychiatry 2001;46(Suppl 1):13S-20S
7. World Health Organization. World health report 2001. Mental health: new understanding, new hope. 2001. Geneva: World Health Organization: 2001
8. Stephens T, Joubert N. The economic burden of mental health problems in Canada. Chronic Dis Can 2001;22:18-23
9. Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry 2001;46 (Suppl 1):5S-90S
10. Panzarino PJ, Jr, Nash DB. Cost-effective treatment of depression with selective serotonin reuptake inhibitors. Am J Manag Care 2001;7:173-84
11. Wilde MI, Whittington R. Paroxetine. A pharmacoeconomic evaluation of its use in depression. Pharmacoeconomics 1995;8:62-81
12. Wilde MI, Benfield P. Fluoxetine. A pharmacoeconomic review of its use in depression. Pharmacoeconomics 1998;13:543-61
13. Davis R, Wilde MI. Sertraline. A pharmacoeconomic evaluation of its use in depression. Pharmacoeconomics 1996;10:409-31
14. Trivedi MH, Wan GJ, Mallick R, Chen J, Casciano R, Geissler EC et al. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder. J Clin Psychopharmacol 2004;24:497-506
15. Lenox-Smith A, Conway P, Knight C. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK. Pharmacoeconomics 2004;22:311-9
16. Casciano J, Doyle J, Arikian S, Casciano R. The health economic impact of antidepressant usage from a payer's perspective: a multinational study. Int J Clin Pract 2001;55:292-9
17. Wan GJ, Crown WH, Berndt ER, Finkelstein SN, Ling D. Healthcare expenditure in patients treated with venlafaxine or selective serotonin reuptake inhibitors for depression and anxiety. Int J Clin Pract 2002;56:434-9
18. Crown WH, Treglia M, Meneades L, White A. Long-term costs of treatment for depression: impact of drug selection and guideline adherence. Value Health 2001;4:295-307
19. Crown WH. Antidepressant selection and economic outcome: a review of methods and studies from clinical practice. Br J Psychiatry 2001;42(Suppl):S18- S22
20. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:999-1009
21. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203
22. Rahme E, Joseph L, Kong SX, Watson DJ, LeLorier J. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. Br J Clin Pharmacol 2001;52:185-92
23. Sclar DA, Robison LM, Skaer TL, Galin RS, Legg RF, Nemec NL et al. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization. J Int Med Res 1995;23:395-412
24. Sullivan EM, Griffiths RI, Frank RG, Strauss MI, Herbert RJ, Clouse J et al. One-year costs of second-line therapies for depression. J Clin Psychiatry 2000;61:290-98
25. Statistics Canada. Hospital Statistics: Preliminary Annual Report, 1994-1995. Catalogue No. 83-241-XPB 1996. 1996. Ottawa, Canada, Ministry of Health, Health Statistics Division
26. Association des hôpitaux du Québec. Répertoire des établissements membres de l'Association des hôpitaux du Québec: 2002-2003. 2002
27. Régie de l'Assurance Maladie du Québec. Manuel des médecins omnipraticiens. Direction des services à la clientele professionnelle. Service de l'information professionnelle. 2005. Quebec, Canada, RAMQ
28. Régie de l'Assurance Maladie du Québec (RAMQ). Manuel des médecins spécialistes. Direction des services à la clientele professionnelle. Service de l'information professionnelle. 2005. Québec, Canada, RAMQ
29. Régie de l'Assurance Maladie du Québec (RAMQ). Liste des medicaments, 15 October 2003. Service de l'information aux professionnels, Dépôt légal - Bibliothéque nationale du Canada. 2003. Québec, Canada, RAMQ
30. Ministère de la Santé et des Services Sociaux. Évaluation de la performance économique globale des centres hospitaliers de soins généraux et spécialisés, volet 'clientèle hospitalisée' - résultats 2002-2003. 2003. Gouvernement du Québec
31. Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy 2004;9:197-204
32. Callahan CM, Kroenke K, Counsell SR, Hendrie HC, Perkins AJ, Katon W et al. Treatment of depression improves physical functioning in older adults. J Am Geriatr Soc 2005;53:367-73
33. Ford JD, Trestman RL, Steinberg K, Tennen H, Allen S. Prospective association of anxiety, depressive, and addictive disorders with high utilization of primary, specialty and emergency medical care. Soc Sci Med 2004;58:2145-8
34. Hunkeler EM, Spector WD, Fireman B, Rice DP, Weisner C. Psychiatric symptoms, impaired function, and medical care costs in an HMO setting. Gen Hosp Psychiatry 2003;25:178-84
35. Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther 2003;25:2289-304
36. Schulberg HC, Katon W, Simon GE, Rush AJ. Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research Practice Guidelines. Arch Gen Psychiatry 1998;55:1121-7
37. Depression Guideline Panel. Treatment of major depression. Depression in primary care: detection, diagnoses, and treatment. Vol. 2. Clinical Practice Guideline No. 5. 1993. Rockville, MD: US Dept of Health and Human Services, Public Health Service, and Agency for Health Care Policy and Research, AHCPR publication 93-0550
38. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 2000;157(Suppl):1-45
39. Maj M, Veltro F, Pirozzi R, Lobrace S, Magliano L. Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study. Am J Psychiatry 1992;149:795-800
40. Sturm R, Wells KB. How can care for depression become more cost-effective? JAMA 1995;273:51-8
41. Katon W, Von Korff M, Lin E, Bush T, Ormel J. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992;30:67-76
42. Simon GE, VonKorff M, Wagner EH, Barlow W. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 1993;15:399-408
43. Lawrenson RA, Tyrer F, Newson RB, Fanner RD. The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Affect Disord 2000;59:149-157
44. Joffe RT, Iskedjian M, Einarson TR, O'Brien BJ, Stang MR. Examining the Saskatchewan health drug database for antidepressant use: the case of fluoxetine. Can J Clin Pharmacol 2001;8:146-52
45. Mullins CD, Shaya FT, Meng F, Wang J, Harrison D. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy 2005;25:660-67
46. Bull SA, Hunkeler EM, Lee JY, Rowland CR, Williamson TE, Schwab JR et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother 2002;36:578-84
47. Cardinal H, Monfared AA, Dorais M, LeLorier J. The concept of the 'percent wasted patients' in preventive health strategies. Pharmacoepidemiol Drug Saf 2005; doi:10.1002/pds.1148
48. Health Canada. A report on mental illnesses in Canada; Chapter 2: Mood Disorders. 2002. Ottawa (ON), Health Canada. Available at http://www.phac-aspc. gc.ca/publicat/miic-mmac/. [Accessed 2005 October 11]
49. Demyttenaere K, Enzlin P, Dewe W, Boulanger B, De Bie J, De Troyer W et al. Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events. J Clin Psychiatry 2001;62(Suppl 22):30-33
50. Leon AC, Solomon DA, Mueller TI, Endicott J, Rice JP, Maser JD et al. A 20-year longitudinal observational study of somatic antidepressant treatment effectiveness. Am J Psychiatry 2003;160:727-33
51. Donoghue J, Hylan TR. Antidepressant use in clinical practice: efficacy v. effectiveness. Br J Psychiatry 2001;42(Suppl): S9-S17
52. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a metaanalysis. Br J Psychiatry 2002;180:396-404
53. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41
54. Wong DT, Bymaster FP. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog Drug Res 2002;58:169-222
55. Poret AW, Neslusan C, Ricci JF, Wang S, Khan ZM, Kwong JW. Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants. Value Health 2001;4:362-9
56. Montgomery SA, Entsuah R, Hackett D, Kunz NR, Rudolph RL. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J Clin Psychiatry 2004;65:328-36
57. Klinkman MS, Coyne JC, Gallo S, Schwenk TL. False positives, false negatives, and the validity of the diagnosis of major depression in primary care. Arch Fam Med 1998;7:51-461
58. Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA. National trends in the outpatient treatment of depression. JAMA 2002;287:203-9
59. Jones G. Prescribing and taking medicines. BMJ 2003;327:819
60. Schulberg HC, Madonia MJ, Block MR, Coulehan JL, Scott CP, Rodriguez E et al. Major depression in primary care practice. Clinical characteristics and treatment implications. Psychosomatics 1995;36:129-37